Bioxel Pharma Inc.

Bioxel Pharma Inc.

May 13, 2008 11:27 ET

Bioxel: First International Agreements for Docetaxel

SAINTE-FOY, QUEBEC--(Marketwire - May 13, 2008) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, today announced it has extended its marketing presence in Asia through the execution of letters of intent with two major Korean generic drug companies for docetaxel active pharmaceutical ingredients. Each of these companies achieves sales of over US$1 billion on an annualized basis.

The names of the companies and the terms of these agreements have not been disclosed for proprietary reasons.

Working with its regional marketing representative, Bioxel is actively securing customers for its newest taxane offering in this strategic region. In commenting on this key milestone, Thomas Warden, Vice-President, Sales, Marketing and Regulatory Affairs of Bioxel Pharma, stated: "Since Bioxel began delivering its production of docetaxel using its proprietary semi-synthesis methods, worldwide interest in this blockbuster drug has steadily grown." He continued, saying, "With the use of alternative synthesis processes, like Bioxel's, and as patent protection expires, generic companies throughout the world are preparing to produce this blockbuster oncology drug. Bioxel expects to be at the forefront of this growth."

Forward-Looking Statements

This press release contains forward-looking statements comprising factors of risk and uncertainty likely to materially and/or adversely affect the Corporation's future results. Risks and uncertainties likely to affect Bioxel's development products include legislation, technological developments and the competition. The expectation of the objectives set forth herein is subject to such risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the degree of achievement of financial forecasts.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane active pharmaceutical ingredients and proprietary products for improved cancer therapy. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis and cardiovascular disease.

The TSX Venture Exchange accepts no responsibility for the adequacy or accuracy of this press release.

Contact Information